Edition:
India

Anthera Pharmaceuticals Inc (ANTH.OQ)

ANTH.OQ on NASDAQ Stock Exchange Global Market

1.42USD
22 Jan 2018
Change (% chg)

-- (--)
Prev Close
$1.42
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
69,017
52-wk High
$6.23
52-wk Low
$1.21

Select another date:

Mon, Jan 22 2018

BRIEF-Anthera Announces Positive Outcome Of Second Interim Futility Analysis In The Phase 3 Sollpura Study

* ANTHERA ANNOUNCES POSITIVE OUTCOME OF SECOND INTERIM FUTILITY ANALYSIS IN THE PHASE 3 RESULT CLINICAL STUDY OF SOLLPURA: STUDY ON SCHEDULE FOR TOPLINE DATA THIS QUARTER

BRIEF-683 Capital Management Reports 6.1 Pct Passive Stake In Anthera Pharma

* 683 CAPITAL MANAGEMENT, LLC REPORTS A 6.1 PERCENT PASSIVE STAKE IN ANTHERA PHARMACEUTICALS INC AS OF JAN 8 - SEC FILING Source text: (http://bit.ly/2mOAqQ5)

BRIEF-Anthera Pharma Appoints Patrick Murphy As Senior Vice President, Manufacturing

* ANTHERA PHARMACEUTICALS ANNOUNCES APPOINTMENT OF PATRICK MURPHY AS SENIOR VICE PRESIDENT, MANUFACTURING Source text for Eikon: Further company coverage:

BRIEF-Anthera Pharmaceuticals Announces Positive Outcome In The Phase 3 Result Clinical Study Of Sollpura

* ANTHERA PHARMACEUTICALS ANNOUNCES POSITIVE OUTCOME OF INTERIM FUTILITY ANALYSIS IN THE PHASE 3 RESULT CLINICAL STUDY OF SOLLPURA

BRIEF-Anthera Pharmaceuticals files for resale of up to 28.6 million shares of co's common stock

* Anthera Pharmaceuticals Inc files for resale of up to 28.6 million shares of co's common stock by the selling stockholders‍​ Source text: (http://bit.ly/2mmbjHr) Further company coverage:

BRIEF-ANTHERA PHARMA REPORTS Q3 LOSS PER SHARE $0.58

* ANTHERA PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND REPORTS 2017 THIRD QUARTER FINANCIAL RESULTS

BRIEF-Armistice Capital reports 5.6 percent passive stake in Anthera Pharma

* Armistice Capital, Llc reports 5.6 percent passive stake in Anthera Pharmaceuticals Inc as on October 24, 2017 - SEC filing‍​ Source text: (http://bit.ly/2A4C2Kr) Further company coverage:

BRIEF-Anthera Pharmaceuticals announces pricing of $15 mln private placement offering

* Anthera Pharmaceuticals announces pricing of $15 million private placement offering

BRIEF-Anthera Pharma surpasses 50 pct milestone for screening of patients in result phase 3 clinical study of Sollpura in cystic fibrosis

* Anthera Pharmaceuticals surpasses 50% milestone for screening of patients in result phase 3 clinical study of Sollpura in cystic fibrosis

BRIEF-Anthera announces top line final data from extension period of phase 2 bright-SC study of blisibimod in patients with iGa nephropathy

* Anthera announces top line final data from the extension period of the phase 2 bright-sc study of blisibimod in patients with IgA nephropathy

Select another date: